Back to Investors
E

Eos

Venture Capital

Portfolio

2

companies


Portfolio companies

Chemify

Chemify

Chemify develops automated systems that digitise and program chemical synthesis.

LT

Laverock Therapeutics

Laverock Therapeutics develops a gene silencing platform for programmable advanced therapies.


Recent investments

Series B
£37.0M

The oversubscribed round will scale automated laboratories and molecular design operations.

"Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery. Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing."
— Lee Cronin, CEO and Founder
Seed
£13.5M

Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.

"GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments."
— David Venables, CEO